Skip to content
Medical Health Aged Care

Monash Expert: Understanding Australia’s COVID-19 epidemics

Monash University < 1 mins read

As the world deals with a new Covid-19 variant, XEC, new Monash University-led research has shown how important short-lived immunity and immune-escape of new variants have been to driving waves of transmission in Australia.

Available to comment:

Associate Professor James Trauer, Head of the Epidemiological Modelling Unit for the School of Public Health and Preventive Medicine
Contact: +613 9903 4840, or [email protected]  
Read more of Associate Professor Trauer’s commentary in Monash Lens.

  • The status of COVID-19 in Australia now
  • The likely impact of COVID-19 moving forward
  • The need for continued vaccination

The following can be attributed to Associate Professor Trauer:

“Our research showed that Australia's major Omicron waves in 2022 were driven by substantial immune-escape of new variants combined with immunity that protected against infection only lasting around three to four months.

“The ‘shadow lockdown’ in summer 2021-2022, when Australians reduced their social interaction in the absence of a government mandate, likely protected us from a considerably larger first epidemic wave. Only around 20 to 40 per cent per cent of all COVID-19 episodes were notified through our surveillance systems, even with our highest levels of testing.

“I think ATAGI’s current guidelines strike the right balance and that people should get vaccinated if they are at-risk and eligible. As the virus continues to evolve, the more recent vaccines are more protective against the current variants - so it's more important if you haven't been vaccinated since the start of last year.” 

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or [email protected]

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.